Palvella Therapeutics, Inc. (PVLA) — Stock Score Summary

Palvella Therapeutics, Inc. (PVLA) has a MoatMap StockRank of 24/100 based on Quality (36/100), Value (24/100), and Momentum (51/100) factor scores. The current signal is SELL. Palvella Therapeutics is a clinical-stage biopharmaceutical company. It lacks commercialized products, recurring revenues, and a proven economic moat, failing our fundamental quality and margin of safety screens.

Palvella Therapeutics, Inc. is a biotechnology company focused on developing and commercializing therapeutics for rare, severe genetic skin diseases. Its lead product candidate, PTX-022, targets epidermolysis bullosa simplex (EBS), a debilitating genetic disorder with high unmet medical need. The company's focus on orphan diseases grants it potential for market exclusivity and accelerated regulatory pathways, positioning it in a specialized, high-barrier-to-entry biopharmaceutical niche.

Key Financial Metrics

Price$104.37
Market Cap$1.7B
P/E (Forward)-17.18
Price/Book7.07
Return on Equity-34.2%
Return on Invested Capital-74.5%
Debt/Equity8.77
Gross Margin0.0%
Operating Margin0.0%
Free Cash Flow$-22M

Palvella Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is Palvella Therapeutics, Inc.’s (PVLA) StockRank?
MoatMap’s StockRank for Palvella Therapeutics, Inc. (PVLA) is 24/100, with a Sell signal. It is a composite of Quality (36), Value (24), and Momentum (51) factor ranks across MoatMap’s 19,000+ stock universe.
Does Palvella Therapeutics, Inc. have an economic moat?
Palvella Therapeutics, Inc. (PVLA) has a Quality factor score of 36/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage — the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is Palvella Therapeutics, Inc. a buy, hold, or sell?
MoatMap’s current signal for Palvella Therapeutics, Inc. (PVLA) is Sell, based on a StockRank of 24/100. Signals are derived mechanically from the StockRank composite and should be one input among many — combine with your own thesis on management, competitive position, and valuation.
What sector is Palvella Therapeutics, Inc. in?
Palvella Therapeutics, Inc. (PVLA) operates in the Healthcare sector, specifically the Biotechnology industry (United States).
Browse all ranked stocksPVLA deep dive reportAI ChampionsHow we score stocksSense-check another stock